Key terms
About PROK
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PROK news
Mar 25
4:23pm ET
ProKidney Bolsters Leadership with Expert EVP, Enhances Operations
Mar 25
6:24am ET
ProKidney appoints Ulrich Ernst as EVP, technical operations
Mar 23
10:36am ET
Buy Rating Affirmed for ProKidney Amidst Strategic Clinical Advancements and Solid Financial Outlook
Mar 21
7:57pm ET
ProKidney reports FY23 EPS (57c), consensus (65c)
Mar 06
8:26pm ET
ProKidney assumed with an Equal Weight at Morgan Stanley
Mar 06
6:20am ET
Analysts Conflicted on These Healthcare Names: ProKidney (PROK), Gritstone Oncology (GRTS) and MicroPort Scientific (OtherMCRPF)
Feb 12
4:28pm ET
ProKidney Approves New Equity Incentives to Retain Key Staff
Jan 07
5:41am ET
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
Jan 02
9:32am ET
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
Jan 02
8:50am ET
ProKidney downgraded to Neutral from Buy at BofA
Dec 31
5:25am ET
ProKidney (PROK) Receives a Buy from BTIG
No recent press releases are available for PROK
PROK Financials
Key terms
Ad Feedback
PROK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PROK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
